About ZYUS Life Sciences
ZYUS Life Sciences is a publicly listed company based in Saskatoon (Canada) founded in 2018 by Brent Zettl. Cannabis-derived therapeutics for multiple indications are developed. ZYUS Life Sciences has raised $19.5 million across 10 funding rounds. ZYUS Life Sciences has completed 1 acquisition, including Revon Systems. Its chief executive, as recorded, is Brent Zettl. Its focus areas include HealthTech, Cannabis HealthTech, Cannabinoid Therapeutics and Diversified. Its competitors include Avicanna and Aleafia Health; 1 of its 2 listed competitors has raised funding.
Company details
ZYUS Life Sciences was founded in 2018 in Saskatoon, Canada, within the biotechnology sector. Cannabis-derived therapeutics are developed for various medical indications, with emphasis on cannabinoid-based products and protein-based formulations. Targeted relief is provided to patients through these innovations. The lead candidate, Trichomylin, is designed to address chronic pain. Operations center on research and formulation development in this specialized field.
- Annual Revenue$295.8 K (USD)-15.8as on Dec 31, 2025
- Net Profit-$15.87 M (USD)35.72as on Dec 31, 2025
- EBITDA-$8.22 M (USD)8.81as on Dec 31, 2025
- Total Equity Funding$19.5M (USD)
in 10 rounds
- Investments & Acquisitions
Funding Insights of ZYUS Life Sciences
ZYUS Life Sciences has successfully raised a total of $19.5M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19.5M
- Total Rounds 10
- First Round $2.37M
(May 2019)
All 10 funding rounds of ZYUS Life Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $207,047 | Post-IPO | – | – | – |
| Nov 2025 | $1.06M | Post-IPO | – | – | – |
| Jul 2025 | $233,014 | Post-IPO | – | – | – |
| Jun 2025 | $182,447 | Post-IPO | – | – | – |
| May 2025 | $574,999 | Post-IPO | – | – | – |
| May 2025 | $578,841 | Post-IPO | – | – | – |
| Aug 2024 | $2.44M | Post-IPO | – | – | – |
| Nov 2021 | $2.07M | Series A | – | – | – |
| Jan 2021 | $15.07M | Series A | – | – | – |
| May 2019 | $2.37M | Seed | – | – | – |
People of ZYUS Life Sciences
9 people are tracked at ZYUS Life Sciences (7 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Brent Zettl | Founder & CEO | Leadership |
Lionel Marks De Chabris | Chief Medical Officer | Leadership |
Keith Carpenter | Chief Strategy and Investment Officer | Leadership |
John Knowles Cpa, Ca | Director | Leadership |
John Hyshka | CFO | Leadership |
John Hiebert | Director of Corporate Security | Leadership |
Michael Boyenko | Director Of Business Development | Leadership |
Christina W. | Senior Executive Assistant | Team |
Landon Pastushok | Senior Scientist, Early Drug Development | Team |
Complete people profiles for ZYUS Life Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ZYUS Life Sciences
ZYUS Life Sciences is a publicly listed company on the TSXV with ticker symbol ZYUS in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Aug 2023
- Listed onOTCMKTS: ZLSCF
- Listed entityZYUS Life Sciences Corporation
- Exchange sectorHealth technology
- ISINCA9899601095
- Share price0.50 CAD (-16.67% on the day) · 2026-10-09
- Market capitalisation40,261,406.00 CAD
- EPS (diluted, trailing year)-0.24 CAD
- Volume (last session)10,595
Financials of ZYUS Life Sciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 405,000 CAD | -21.7M CAD | -11.2M CAD |
| 2024 | 481,000 CAD | -33.8M CAD | -12.3M CAD |
| 2023 | 351,000 CAD | -42.6M CAD | -15.9M CAD |
| 2022 | 298,000 CAD | -24.7M CAD | -12.3M CAD |
| 2021 | 350,560 CAD | -228,460 CAD |
Detailed financial statements for ZYUS Life Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ZYUS Life Sciences
ZYUS Life Sciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Revon Systems.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Digital therapeutic solutions for chronic care management are offered. | revon.ai | Crestwood, United States | 2013 | Jul 2019 | •••• |
Complete acquisition details for ZYUS Life Sciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of ZYUS Life Sciences
5 dated milestones of ZYUS Life Sciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded ZYUS Life Sciences is founded.
- Funding First funding round of $2.4M.
- Acquisition Acquires Revon Systems.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of ZYUS Life Sciences
ZYUS Life Sciences has 2 listed competitors in our database, 1 of them funded. They include Avicanna and Aleafia Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| avicanna.com | 2016 | Toronto, Canada | $5.94M | Plant-derived cannabinoid products are developed for medical and consumer uses. | ||
| aleafiahealth.com | 2007 | Vaughan, Canada | Cultivator and producer of cannabis plant for consumer wellness and research applications |
Detailed competitors of ZYUS Life Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cannabis Health Tech Ecosystem
2 companies that operate in the same segment as ZYUS Life Sciences (Cannabis Health Tech Ecosystem) in Canada, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Cannabis products are provided to support consumer wellness and health. | 2013 | Smiths Falls, Ontario, Canada | USD 204.24 M | 960 | ||
Provider of cannabis products, brands, and international business development investments | 2013 | Moncton, New Brunswick, Canada | USD 186.16 M | 898 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zyus Life Sciences
Complete news archive for ZYUS Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ZYUS Life Sciences
ZYUS Life Sciences was founded in 2018 and raised its 1st funding round 1 year after it was founded.
ZYUS Life Sciences is headquartered in Saskatoon, Canada. It is registered at Saskatoon, Saskatchewan, Canada.
Brent Zettl is the CEO of ZYUS Life Sciences, as recorded in our data. They have also founded this company.
ZYUS Life Sciences is a funded company, having raised a total of $19.5M across 10 funding rounds to date. The company's 1st funding round was a Seed of $2.37M, raised on May 2019.
Annual revenue of ZYUS Life Sciences is $295.8K as on Dec 31, 2025.
ZYUS Life Sciences was founded in 2018 in Saskatoon, Canada, within the biotechnology sector. Cannabis-derived therapeutics are developed for various medical indications, with emphasis on cannabinoid-based products and protein-based formulations. Targeted relief is provided to patients through these innovations. The lead candidate, Trichomylin, is designed to address chronic pain. Operations center on research and formulation development in this specialized field.
ZYUS Life Sciences's top competitors include Avicanna and Aleafia Health.
Yes, ZYUS Life Sciences is publicly traded on TSXV under the ticker symbol ZYUS.
ZYUS Life Sciences has made 1 acquisition, including Revon Systems.